Skip to content
Top Globe News – Lifestyle
Author:
Kowa Company Ltd.
Selective PPARα Modulator “K-808” (Pemafibrate) Granted “Breakthrough Therapy” Designation by the U.S. Food and Drug Administration (FDA) As a Treatment for Primary Biliary Cholangitis
June 30, 2026